e-learning resources

ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Prognostic factors and outcomes in pulmonary embolism

Poster Discussion
Chairs: D. Jiménez Castro (Madrid, Spain), O. Sanchez (Paris, France)

Download all media

Download all media

Age-Adjusted D-Dimer Cut Off: Could this prove cost-effective and safe for our Emergency Units?Authors:Mills M, Downey C , Townley S, Kasis A, Dutt T, Gautam M.Introduction:A D-dimer test result (conventionally up to 500 µg/L) is an important component of the diagnostic work-up for patients with suspected VTE, however, it is well known that D-Dimer levels rise with age. Although a negative D-Dimer in conjunction with a clinical probability score can be effective at excluding DVT/PE, studies have proposed that the use of an age-adjusted cut off can increase the number of patients excluded from further testing with a low likelihood of subsequent VTE.This study looked at unselected D-dimer requests from the Emergency department (ED) for patients with suspected DVT/PE to assess the potential impact of introducing age-adjusted D-dimer cut off limits. A. Kasis (Liverpool, United Kingdom)
Is it really save to apply the age-adjusted D-dimer cutoff for ruling out pulmonary embolism? E. van de Stadt (Enschede, Netherlands)
Pulmonary Embolism Lysis Team (PELT): Guiding thrombolysis in Sub-Massive PE (SMPE) T. Mason (London, United Kingdom)
Short-term mortality in patients with acute symptomatic pulmonary embolism A. Jaureguizar Oriol (MADRID, Spain)
High prevalence of chronic breathlessness following submassive pulmonary embolism P. Flood-Page (CARDIFF, United Kingdom)
In patients with intermediate-low risk pulmonary embolism: cardiac enzyme or right ventricle dysfunction or sPESI F. Öztuna (Trabzon, Turkey)
Incidence of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) at six months of a Pulmonary Embolism (PE). OSIRIS Study
Prognostic value of right ventricular dilatation in patients with low risk pulmonary embolism B. Côté (Québec, Canada)
Pulmonary embolism in England 1998-2015: increasing incidence and declining mortality. S. Wort (Hampton, United Kingdom)
Clinical and Epidemiological Features of Tumor and Non-tumor Patients Complicated with Pulmonary Embolism Y. Havlucu (Manisa, Turkey)
Different mortality, recurrence and bleeding between cancer and non cancer patients with pulmonary embolism (PE): 1 year follow-up. L. Marconi (Pisa, PI, Italy)
Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes H. Oflaz Hezer (ANKARA, Turkey)
Prevalence and clinical predictors of persistent perfusion defects after acute pulmonary embolism P. Ramirez Martin (Spain)

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.